

Jubilant Draximage Radiopharmacies Inc.
Balance Sheet as at 31 March 2023
(All amounts in USD, unless otherwise stated)

	Notes	As at 31 March 2023	As at 31 March 2022
ASSETS			
Non-current assets			
Property, plant and equipment	3	-	-
Capital work-in-progress	3	-	-
Goodwill	4	-	-
Other intangible assets	4	-	-
Right-of-use assets	5	-	-
Financial assets			
i. Loans	6	4,500,000	4,500,000
Total non-current assets		4,500,000	4,500,000
Current assets			
Financial assets			
i. Cash and cash equivalents	7	141,405	248,993
ii. Other financial assets	8	529,947	336,449
Total current assets		671,352	585,442
Total assets		5,171,352	5,085,442
EQUITY AND LIABILITIES			
Equity			
Equity share capital	9	114,505,000	114,505,000
Other equity		(109,519,316)	(109,694,611)
Total equity		4,985,684	4,810,389
Liabilities			
Current liabilities			
Financial liabilities			
i. Trade payables	10	171,509	262,174
Current tax liabilities (net)		14,159	12,879
Total current liabilities		185,668	275,053
Total liabilities		185,668	275,053
Total equity and liabilities		5,171,352	5,085,442

Jubilant Draximage Radiopharmacies Inc.
Statement of Profit and Loss for the year ended 31 March 2023
(All amounts in USD, unless otherwise stated)

	Notes	For the year ended 31 March 2023	For the year ended 31 March 2022
Revenue from operations	11	-	30,049,232
Other income	12	194,807	194,657
Total income		194,807	30,243,889
Expenses			
Cost of materials consumed	13	-	14,743,474
Purchases of stock-in-trade	14	-	2,854,687
Employee benefits expense	15	-	10,324,822
Finance costs	16	-	174,350
Depreciation and amortisation expense	17	-	1,557,180
Other expenses	18	9,964	5,145,173
Total expenses		9,964	34,799,686
Profit before tax		184,843	(4,555,797)
Tax expense			
- Current tax		9,548	128,301
- Deferred tax (credit)/charge		-	23,884,881
Total tax expense		9,548	24,013,182
Profit for the year		175,295	(28,568,979)
Other comprehensive loss for the year, net of tax		-	-
Total comprehensive income for the year		175,295	(28,568,979)

Jubilant Draximage Radiopharmacies Inc.
Statement of Changes in Equity for the year ended 31 March 2023
(All amounts in USD, unless otherwise stated)

				Amount
A. Equity share capital				
Balance as at 1 April 2021				114,505,000
Changes in equity share capital during the year				-
Balance as at 31 March 2022				114,505,000
Changes in equity share capital during the year				-
Balance as at 31 March 2023				114,505,000
B. Other equity				
	Reserves and surplus			Total
	Merger reserve	Other capital reserve	Retained earnings	
Balance as at 1 April 2021	-	66,454	(87,761,266)	(87,694,812)
Profit for the year	-	-	(28,568,979)	(28,568,979)
Other comprehensive income/(loss)	-	-	-	-
Total comprehensive income for the year	-	-	(28,568,979)	(28,568,979)
Sale of business (refer note below)	6,569,180	-	-	6,569,180
Tax impact on sale of business	(2,337,538)	2,337,538	-	-
Balance as at 31 March 2022	4,231,642	2,403,992	(116,330,245)	(109,694,611)
Profit for the year	-	-	175,295	175,295
Other comprehensive income/(loss)	-	-	-	-
Total comprehensive income for the year	-	-	175,295	175,295
Balance as at 31 March 2023	4,231,642	2,403,992	(116,154,950)	(109,519,316)

Note:

Pursuant to the Asset Purchase Agreement, effective from 1 June 2021, the Company transferred substantially all the assets and liabilities comprising the Radiopharmacy Business to Jubilant DraxImage Inc., Canada (a fellow subsidiary company) amounting to 19,191,627 for a total consideration of 25,760,807 (including post-closing adjustments) and recorded the difference under Merger Reserve.

Jubilant Draximage Radiopharmacies Inc.
Statement of Cash Flows for the year ended 31 March 2023
(All amounts in USD, unless otherwise stated)

	As at 31 March 2023	As at 31 March 2022
A. Cash flow from operating activities		
Net profit / (loss) before tax	184,843	(4,555,797)
Adjustments:		
Depreciation and amortisation expense	-	1,557,180
Finance costs	-	174,350
Interest income	(194,807)	(194,657)
	(194,807)	1,536,873
Operating cash flow before working capital changes	(9,964)	(3,018,924)
Increase in trade receivables, loans, other financial assets and other assets	-	(1,144,782)
Increase in inventories	-	(327,278)
Decrease in trade payables, other financial liabilities, other liabilities and provisions	(98,412)	(11,453,290)
Cash used in operations	(108,376)	(15,944,274)
Income tax paid (net of refund)	(521)	-
Net cash used in operating activities	(108,897)	(15,944,274)
B. Cash flow from investing activities		
Purchase of property, plant and equipment and other intangible assets	-	(866,910)
Loans repaid by related party	-	5,700,000
Movement in other bank balances	-	160,000
Interest received	1,309	-
Net cash generated from investing activities	1,309	4,993,090
C. Cash flow from financing activities		
Payment of lease liabilities	-	(912,044)
Business sale consideration	-	5,760,809
Finance costs paid	-	(147,666)
Net cash generated from financing activities	-	4,701,099
Net decrease in cash and cash equivalents (A+B+C)	(107,588)	(6,250,085)
Cash and cash equivalents at the beginning of year	248,993	6,499,078
Cash and cash equivalents at the end of the year	141,405	248,993

Note 1: Corporate information

Jubilant Draximage Radiopharmacies Inc. ("the Company") was incorporated on March 8, 2017 in the United States of America ("USA") under the local laws of Delaware. The Company is a wholly owned subsidiary of Jubilant Pharma Holdings Inc., a Delaware Corporation ("the holding company") whose ultimate parent company is Jubilant Pharmova Limited, a company incorporated in India. The Company was amongst largest radiopharmacy network in the US with 46 pharmacies under its fold.

Pursuant to the Asset Purchase Agreement, effective from 1 June 2021, the Company transferred substantially all the assets and liabilities comprising the Radiopharmacy Business to Jubilant DraxImage Inc., Canada (a fellow subsidiary company).

Note 2. Significant accounting policies

This note provides a list of the significant accounting policies adopted in the preparation of these financial statements. The accounting policies adopted are consistent with those of the previous financial year.

(a) Basis of preparation

(i) Statement of compliance

These financial statements with limited information have been prepared solely for consideration in the consolidated financial statements of the Ultimate Parent Company. These financial statements have been prepared in accordance with the Ultimate Parent's accounting policies which are in agreement with the recognition and measurement principles laid down under the Companies (Indian Accounting Standards) Rules, 2015, as amended.

(ii) Historical cost convention

These financial statements have been prepared under historical cost convention on accrual basis, unless otherwise stated.

(b) Functional and presentation currency

Items included in the financial statements of the Company are measured using the currency of the primary economic environment in which the entity operates (i.e. the "functional currency"). The functional currency of the Company is U.S. Dollars ("USD"). These financial statements are presented in USD.

(c) Current versus non-current classification

The Company presents assets and liabilities in the Balance Sheet based on current/non-current classification.

An asset is treated as current when:

- It is expected to be realised or intended to be sold or consumed in normal operating cycle;
- It is held primarily for the purpose of trading;
- It is expected to be realised within twelve months after the reporting period; or
- It is cash or cash equivalent unless restricted from being exchanged or used to settle a liability for at least twelve months after the reporting period.

The Company classifies all other assets as non-current.

A liability is current when:

- It is expected to be settled in normal operating cycle;
- It is held primarily for the purpose of trading;
- It is due to be settled within twelve months after the reporting period; or
- There is no unconditional right to defer the settlement of the liability for at least twelve months after the reporting period.

The Company classifies all other liabilities as non-current.

Deferred tax assets and liabilities are classified as non-current assets and liabilities respectively.

The operating cycle is the time between the acquisition of assets for processing and their realisation in cash and cash equivalents. The Company has identified twelve months as its operating cycle for the purpose of current-non-current classification of assets and liabilities.

Jubilant Draximage Radiopharmacies Inc.
Notes to the financial statements for the year ended 31 March 2023
(All amounts in USD, unless otherwise stated)

Note 3: Property, plant and equipment and capital work-in-progress

Description	Plant and machinery	Furniture and fixtures	Office equipment	Total	Capital work-in-progress
Gross carrying amount as at 1 April 2021	4,497,095	9,166,998	1,055,156	14,719,249	1,958,775
Additions	99,180	1,335,750	173,231	1,608,161	833,015
Deductions	-	-	-	-	(1,608,161)
Transferred on sale of business	(4,596,275)	(10,502,748)	(1,228,387)	(16,327,410)	(1,183,629)
Gross carrying amount as at 31 March 2022	-	-	-	-	-
Accumulated depreciation as at 1 April 2021	2,576,966	3,800,330	456,747	6,834,043	-
Depreciation charge for the year	144,019	249,898	21,958	415,875	-
Transferred on sale of business	(2,720,985)	(4,050,228)	(478,705)	(7,249,918)	-
Accumulated depreciation as at 31 March 2022	-	-	-	-	-
Net carrying amount as at 31 March 2022	-	-	-	-	-

Description	Plant and machinery	Furniture and fixtures	Office equipment	Total	Capital work-in-progress
Gross carrying amount as at 1 April 2022	-	-	-	-	-
Additions	-	-	-	-	-
Deductions	-	-	-	-	-
Gross carrying amount as at 31 March 2023	-	-	-	-	-
Accumulated depreciation as at 1 April 2022	-	-	-	-	-
Depreciation charge for the year	-	-	-	-	-
Accumulated depreciation as at 31 March 2023	-	-	-	-	-
Net carrying amount as at 31 March 2023	-	-	-	-	-

Jubilant Draximage Radiopharmacies Inc.

Notes to the financial statements for the year ended 31 March 2023

(All amounts in USD, unless otherwise stated)

Note 4: Goodwill, other intangible assets and intangible assets under development

Description	Goodwill	Other intangible assets		Total
		Acquired trademarks/ trade names and customer contracts	Softwares	
Gross carrying amount as at 1 April 2021	11,373,834	1,310,000	1,627,715	2,937,715
Additions during the year	-	-	5,141	5,141
Deductions	-	-	-	-
Transferred on sale of business	(11,373,834)	(1,310,000)	(1,632,856)	(2,942,856)
Gross carrying amount as at 31 March 2022	-	-	-	-
Accumulated depreciation as at 1 April 2021	-	639,620	809,843	1,449,463
Depreciation charge for the year	-	14,449	57,281	71,730
Transferred on sale of business	-	(654,069)	(867,124)	(1,521,193)
Accumulated depreciation as at 31 March 2022	-	-	-	-
Net carrying amount as at 31 March 2022	-	-	-	-

Description	Goodwill	Other intangible assets		Total
		Acquired trademarks/ trade names and customer contracts	Softwares	
Gross carrying amount as at 1 April 2022	-	-	-	-
Additions during the year	-	-	-	-
Deductions	-	-	-	-
Gross carrying amount as at 31 March 2023	-	-	-	-
Accumulated depreciation as at 1 April 2022	-	-	-	-
Depreciation charge for the year	-	-	-	-
Accumulated depreciation as at 31 March 2023	-	-	-	-
Net carrying amount as at 31 March 2023	-	-	-	-

Jubilant Draximage Radiopharmacies Inc.**Notes to the financial statements for the year ended 31 March 2023****(All amounts in USD, unless otherwise stated)****Note 5: Right-of-use assets****The details of the right-of-use assets held by the Company is as follows:**

	As at		As at	
	31 March 2023		31 March 2022	
	Depreciation	Net block	Depreciation	Net block
Buildings	-	-	716,993	-
Office equipment	-	-	11,335	-
Vehicles	-	-	341,247	-
	-	-	1,069,575	-

Amount recognised in profit or loss:

	As at	As at
	31 March 2023	31 March 2022
Interest on lease liabilities	-	147,666
Rental expense relating to short-term leases	-	49,913
	-	197,579

Amount recognised in statement of cash flows:

	As at	As at
	31 March 2023	31 March 2022
Total cash outflow for leases	-	1,109,623

Jubilant Draximage Radiopharmacies Inc.
Notes to the financial statements for the year ended 31 March 2023
(All amounts in USD, unless otherwise stated)

Note 6: Non-current loans

	As at	As at
	31 March 2023	31 March 2022
Unsecured, considered good		
Loan to related parties	4,500,000	4,500,000
Total non-current loans	4,500,000	4,500,000

Note 7: Cash and cash equivalents

	As at	As at
	31 March 2023	31 March 2022
Balances with banks		
- in current accounts	141,405	248,993
Total cash and cash equivalents	141,405	248,993

Note 8: Other current financial assets

	As at	As at
	31 March 2023	31 March 2022
Recoverable from related parties	529,947	336,449
Total other current financial assets	529,947	336,449

Jubilant Draximage Radiopharmacies Inc.
Notes to the financial statements for the year ended 31 March 2023
(All amounts in USD, unless otherwise stated)

Note 9: Equity share capital

	As at 31 March 2023	As at 31 March 2022
Authorised		
3000 Common stock of no par value	-	-
	-	-
Issued and subscribed		
200 Common stock of no par value	114,505,000	114,505,000
	114,505,000	114,505,000
Movement in equity share capital	No. of shares	Amount
As at 1 April 2021	200	114,505,000
Additions during the year	-	-
As at 31 March 2022	200	114,505,000
Additions during the year	-	-
As at 31 March 2023	200	114,505,000

Terms and rights attached to equity shares

The Company has only one class of Common stock referred to herein as equity shares. Each holder of common stock is entitled to one vote per common stock. In the event of liquidation of the Company, the stockholders shall be entitled to receive all of the remaining assets of the Company, after distribution of all preferential amounts, if any. Such amounts will be in proportion to the number of common stock of equity shares held by the stockholders.

Details of shareholders holding more than 5% shares in the Company:

	As at 31 March 2023		As at 31 March 2022	
	No. of shares	% holding	No. of shares	% holding
Jubilant Pharma Holdings Inc., USA - the holding company	200	100.00%	200	100.00%
Common stock of no par value				

Note 10(b): Nature and purpose of other equity

Merger reserve

Represents difference between the consideration and carrying amount of net assets/liabilities for transactions among entities under common control to transfer out/in of any business or shares of entities under common control.

Other capital reserve

Accumulated capital surplus not available for distribution of dividend and expected to remain invested permanently. This also includes reserves arising on transaction with owners of the Company (other than those accounted for in merger reserve).

Retained earnings

Retained earnings represent the amount of accumulated earnings/(loss) of the Company.

Jubilant Draximage Radiopharmacies Inc.
Notes to the financial statements for the year ended 31 March 2023
(All amounts in USD, unless otherwise stated)

Note 10: Trade payables		
	As at	As at
	31 March 2023	31 March 2022
Current		
Dues to relates parties	170,809	261,474
Dues to others	700	700
Total trade payables	171,509	262,174

Jubilant Draximage Radiopharmacies Inc.
Notes to the financial statements for the year ended 31 March 2023
(All amounts in USD, unless otherwise stated)

Note 11: Revenue from operations

	For the year ended 31 March 2023	For the year ended 31 March 2022
Sale of products	-	29,193,672
Sale of services	-	515,538
Other operating revenue	-	340,022
Total revenue from operations	-	30,049,232

Note 12: Other income

	For the year ended 31 March 2023	For the year ended 31 March 2022
Interest income	194,807	194,657
Total other income	194,807	194,657

Note 13: Cost of materials consumed

	For the year ended 31 March 2023	For the year ended 31 March 2022
Raw materials consumed	-	14,743,474
Total cost of materials consumed	-	14,743,474

Note 14: Purchase of stock-in-trade

	For the year ended 31 March 2023	For the year ended 31 March 2022
Purchase of stock-in-trade	-	2,854,687
Total purchase of stock-in-trade	-	2,854,687

Note 15: Employee benefits expense

	For the year ended 31 March 2023	For the year ended 31 March 2022
Salaries, wages, bonus, gratuity and allowances	-	8,610,531
Contribution to provident fund, superannuation and other funds	-	995,887
Staff welfare expenses	-	718,404
Total employee benefits expense	-	10,324,822

Note 16: Finance costs

	For the year ended 31 March 2023	For the year ended 31 March 2022
Interest expense	-	174,350
Total finance costs	-	174,350

Note 17: Depreciation and amortisation expense

	For the year ended 31 March 2023	For the year ended 31 March 2022
Depreciation of property, plant and equipment	-	415,875
Amortisation of intangible assets	-	71,730
Depreciation on right of use assets	-	1,069,575
Total depreciation and amortisation expense	-	1,557,180

Jubilant Draximage Radiopharmacies Inc.
Notes to the financial statements for the year ended 31 March 2023
(All amounts in USD, unless otherwise stated)

Note 18: Other expenses

	For the year ended	For the year ended
	31 March 2023	31 March 2022
Power and fuel	-	402,577
Rental charges	-	49,913
Rates and taxes	1,733	272,162
Insurance	-	280,806
Advertisement, publicity and sales promotion	-	1,813
Travel and conveyance	-	88,722
Repairs and maintenance:		
i. Plant and machinery	-	155,378
ii. Buildings	-	24,974
iii. Others	-	89,551
Office expenses	-	251,849
Vehicle running and maintenance	-	155,087
Printing and stationery	-	66,979
Telephone and communication charges	-	335,996
Staff recruitment and training	-	106,260
Legal and professional fees	7,735	1,012,797
Freight and forwarding (including ocean freight)	-	866,185
Bank charges	496	203,782
Commission on sales	-	696,315
Miscellaneous expenses	-	84,027
Total other expenses	9,964	5,145,173